Table 1. Distribution of demographic and clinical outcomes of patients according to RV status.
| Variable | Overall | RV-positive | RV-negative | P-value* |
|---|---|---|---|---|
| (n = 1,414†) | (n = 428†) | (n = 986†) | ||
| Center | 0.024* | |||
| AUBMC | 157 (11.1%) | 44 (28.0%) | 113 (72.0%) | 0.030*£ |
| Hammoud Hospital | 209 (14.8%) | 83 (39.7%) | 126 (60.3%) | |
| Hôtel-Dieu de France University Hospital | 5 (0.4%) | 0 (0.0%) | 5 (100.0%) | |
| Makassed Hospital | 189 (13.4%) | 47 (24.9%) | 142 (75.1%) | |
| Nini Hospital | 556 (39.3%) | 166 (29.9%) | 390 (70.1%) | |
| Nabatieh Hospital | 212 (15.0%) | 65 (30.7%) | 147 (69.3%) | |
| Rafic Hariri University Hospital | 86 (6.1%) | 23 (26.7%) | 63 (73.3%) | |
| Age (months) | 0.984 | |||
| 0–2 | 93 (6.6%) | 30 (32.3%) | 63 (67.7%) | |
| 3–6 | 268 (19.0%) | 79 (29.5%) | 189 (70.5%) | |
| 7–12 | 461 (32.6%) | 137 (29.7%) | 324 (70.3%) | |
| 13–24 | 364 (25.7%) | 112 (30.8%) | 252 (69.2%) | |
| 25–60 | 228 (16.1%) | 70 (30.7%) | 158(69.3%) | |
| Male gender | 786 (55.6%) | 235 (29.9%) | 551 (70.1%) | 0.734 |
| Living in Lebanon | 1350 (95.5%) | 413 (30.6%) | 937 (69.4%) | 0.252 |
| Vesikari score>10 | 1,295 (91.6%) | 398(93.0%) | 898(91.1%) | 0.231 |
| Symptoms | ||||
| Fever | 966 (68.3%) | 266 (62.1%) | 700 (71.1%) | 0.001* |
| Vomiting | 889 (62.9%) | 327 (76.4%) | 562 (57.0%) | <0.001* |
| Diarrhea | 1,288 (91.1%) | 385 (90.0%) | 903 (91.7%) | 0.295 |
| Treatments during hospitalization and at discharge‡ | ||||
| Oral rehydration | 234 (16.6%) | 85 (19.9%) | 149 (15.1%) | 0.028* |
| IV rehydration | 1,379 (97.5%) | 416(97.2%) | 963(97.7%) | 0.600 |
| Antibiotics | 698 (49.4%) | 173(40.4%) | 525(53.2%) | <0.001* |
| Vaccination history | ||||
| Yes (any type and dose) | 255 (18.1%) | 48(11.2%) | 207 (21.0%) | <0.001 |
| RV1 (Rotarix®) | ||||
| 1 dose | 54 (25.0%) | 13 (32.5%) | 41 (23%) | |
| 2 doses | 165 (75.0%) | 27 (67.5%) | 138 (77%) | |
| RV5 (Rotateq®) | 0.973 | |||
| 1 dose | 8 (28.5%) | 2 (28.5%) | 6 (28.6%) | |
| 2 doses | 3 (10.7%) | 1 (14.3%) | 2 (9.5%) | |
| 3 doses | 17 (60.8%) | 4 (57.2%) | 13 (61.9%) | |
| Unknown vaccine | 2 (0.1%) | 2 (0.5%) | 0 (0.0%) | |
| Unvaccinated | 1,157 (81.8%) | 378 (88.3%) | 779 (79.0%) | |
| Duration of hospitalization (days)‡ | 0.106 | |||
| 0–3 | 537 (38.0%) | 145 (33.9%) | 392 (39.8%) | |
| 4–7 | 805 (56.9%) | 261 (61.0%) | 544 (55.2%) | |
| >7 | 72 (5.1%) | 22 (5.1%) | 50 (5.1%) | |
†The sample size per column might not add to the total of that column depending on whether there are some missing data or not.
*Significant at the 5% level.
£P-value excluding Hôtel-Dieu de France University Hospital from the comparison.
‡Percentages are computed within each column (i.e. percentage of treatment within each group of RV+ and RV-).
Abbreviations: AUBMC = American University of Beirut Medical Center.